Efficacy and safety of SGLT2 inhibitors in type 1 diabetes after the introduction of an off-label use protocol for clinical practice
Bayona Cebada A, Nattero-Chávez L, et al.
Diabetes Technol Ther. 2020;22(3):208-15
Leggi
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Bayona Cebada A, Nattero-Chávez L, et al.
Diabetes Technol Ther. 2020;22(3):208-15
Leggi
Sherr JL, Buckingham BA, Forlenza GP, et al.
Diabetes Technol Ther. 2020;22(3):174-84
Leggi
Dauriz M, Morici N, Gonzini L et al.
Am J Med. 2020;133(3):331-339.e2
Leggi
Packer M
American Journal of Medicine. Pub online 12 February 2020
Leggi
Jianhong Z, Xiaoxia Y, Zheng Y, et al.
Lancet Diabetes Endocrinol. 2020;8(3):192-205
Leggi
Maddaloni E, Coleman RL, Agbaje O, et al.
Lancet Diabetes Endocrinol. 2020;8(3):206-15
Leggi
Rodbard D
Diabetes Technol Ther. Pub online 18 February 2020
Leggi
Lepore G, Scaranna C, Corsi A, et al.
Diabetes Technol Ther. Pub online 11 February 2020
Leggi
Rajani A, Sahay M, Bhattacharyya A, Amar A
Diabet Med. Pub. online 3 February 2020
Leggi
Tramunt B, Smati S, Grandgeorge N, et al.
Diabetologia. 2020;63:453-61
Leggi